Temocillin: In vitro activity against 734 selected clinical isolates, including β-lactamase-producing strains

Fuchs, Peter; Barry, Arthur L.; Jones, Ronald N.; Thornsberry, Clyde

doi:10.1016/0732-8893(84)90023-3

Cited by 9 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was already described by Fuchs et al in 1984 and is mentioned in the leaflet of Negaban®. 5 , 15 However, we did not find a significant difference in outcomes between episodes with EKP and non-EKP isolates. These findings are in line with the study results of Balakrishnan et al 19 and Alexandre et al 20 More large-scale clinical studies are needed to substantiate our findings and to determine whether a clinical breakpoint can be set for non-EKP isolates.…”

Section: Discussioncontrasting

confidence: 55%

“…In vitro activity studies have set an MIC 90 of 16 mg/L for Enterobacterales, except for Enterobacter species and S. marcescens where higher MIC 90 values were observed. 15 , 28 , 29 Based on pharmacokinetic studies using Monte Carlo simulations performed on ICU patients, a breakpoint of 8 mg/L was proposed for the standard dosage of 2 g q12h and a breakpoint of 16 mg/L for the high dosage of 2 g q8h. 26 , 30 When comparing the outcomes of episodes caused by strains with an MIC value ≤8 mg/L versus those with an MIC of 16 mg/L, we did not observe a significant difference.…”

Section: Discussionmentioning

confidence: 99%

“…Temocillin susceptibility was determined by both disc diffusion (Liofilchem, Italy) and Etests (Liofilchem). Breakpoints described by Fuchs et al 8 , 15 were applied for susceptibility reporting. Disc diameters were read by the automatic system SIRscan 2000®, with phenotypic detection of ESBL and AmpC resistance profiles.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Clinical and microbiological evaluation of temocillin for bloodstream infections with Enterobacterales: a Belgian single-centre retrospective study

Oosterbos

Schalkwijk

Thiessen

et al. 2022

JAC-Antimicrobial Resistance

View full text Add to dashboard Cite

Background Expanding the use of temocillin could be an important weapon in the fight against antimicrobial resistance. However, EUCAST defined clinical breakpoints for a limited number of species and only for urinary tract infections (UTI), including urosepsis but excluding severe sepsis and septic shock. Moreover, a dosage of 2 g q8h is advised in most cases. Objectives Evaluation of temocillin use for the treatment of bacteraemia, correlating clinical and microbiological outcomes with infection site, infection severity, temocillin dosage, Enterobacterales species and MIC. Patients and methods All adult patients with blood cultures positive for temocillin-susceptible Enterobacterales and treated with temocillin for ≥72 h from June 2018 until June 2021 were considered for inclusion. The primary outcome was clinical success, defined as resolution of infection signs, no relapse of the same infection and no antibiotic switch due to insufficient clinical improvement. The secondary outcome was microbiological success. Results In total, 182 episodes were included [140 UTI versus 42 non-UTI, 171 Escherichia coli, Klebsiella species (except Klebsiella aerogenes) and Proteus mirabilis (EKPs) versus 11 non-EKPs]. Clinical and microbiological failure were low (8% and 3%, respectively). No difference in outcome was observed for dosages of 2 g q12h versus 2 g q8h, either for EKP versus non-EKP isolates or MIC values ≤8 versus 16 mg/L. Considering only bacteraemia episodes of UTI origin, using the 16 mg/L breakpoint, there was no difference in success rate between regimens of 2 g q12h and 2 g q8h. Conclusions Temocillin 2 g q12h can be successfully used for the treatment of systemic UTI. Prospective studies are needed to assess outcomes and evaluate non-inferiority compared with other broad-spectrum antibiotics in non-UTI infections, including bacteraemia.

show abstract

Section: Discussioncontrasting

confidence: 55%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical and microbiological evaluation of temocillin for bloodstream infections with Enterobacterales: a Belgian single-centre retrospective study

Oosterbos

Schalkwijk

Thiessen

et al. 2022

JAC-Antimicrobial Resistance

View full text Add to dashboard Cite

show abstract

Interpretive criteria for temocillin disk diffusion susceptibility testing

Fuchs

Barry²,

Thornsberry

et al. 1985

Eur. J, Clin. Microbiol.

View full text Add to dashboard Cite

The susceptibility of 677 clinical bacterial isolates to temocillin was determined by broth microdilution and disk diffusion methods for the purpose of evaluating disks with three different temocillin concentrations and determining the temocillin disk diffusion interpretive criteria. The 60 microgram temocillin disk provided the highest interpretive accuracy (96.2%), although the 30 microgram disk differed by having only three (1.2%) additional minor interpretive errors. Based on available temocillin pharmacokinetics and recommended dosage schedules, the minimum inhibitory concentration breakpoints chosen were: greater than or equal to 32 micrograms/ml = resistant and less than or equal to 16 micrograms/ml = susceptible. The corresponding disk diffusion zone diameter breakpoints for the 60 microgram disk were less than or equal to 17 mm and greater than or equal to 21 mm; zone diameters of 18-20 mm were considered intermediate. For the 30 microgram disk these were less than or equal to 15 mm, greater than or equal to 19 mm and 16-18 mm respectively.

show abstract

Desacetylcefotaxime

Kearns¹

1992

Drug Invest

View full text Add to dashboard Cite

At present, desacety1cefotaxime represents the only major metabolite from a third generation cephalosporin that attains and maintains effective antimicrobial plasma and tissue concentrations following therapeutic administration of its parent drug (i.e. cefotaxime). Therapeutic concentrations of desacety1cefotaxime are produced in neonates, infants, children and adults, although because of normal developmental changes in renal function, the plasma clearance of the drug is reduced in neonates and young infants. Previous investigations of the pharmacokinetics of des-acety1cefotaxime have not only demonstrated effective penetration into various tissues and fluids, but also that alterations in plasma protein concentration and/or binding do not appear to alter either the pharmacokinetics or pharmacodynamics of the drug. Consequent to a more prolonged elimination half-life for desacety1cefotaxime (e.g. approximately 1.6h in adults, 2.1 h in infants and children, 9.4h in neonates) as compared to its parent drug, desacety1cefotaxime persists in plasma at concentrations which exceed the minimum concentration inhibiting 50% of organisms (MIC50) for many common paediatric pathogens for 6 to 8 hours following a cefotaxime dose. This property, coupled with excellent stability against many types of i3-lactamases, produces an additive and/or synergistic antimicrobial effect when cefotaxime is used to treat infections caused by many common pathogens. Accordingly, the unique pharmacokinetic and pharmacodynamic properties of desacety1cefotaxime enable, in part, an enhanced therapeutic profile for its parent drug which may permit longer dosing intervals for cefotaxime (i.e. every 8 or 12h) to be used without necessarily compromising efficacy associated with conventional (i.e. every 6h) dosing regimens.

show abstract

Temocillin: In vitro activity against 734 selected clinical isolates, including β-lactamase-producing strains

Cited by 9 publications

References 14 publications

Clinical and microbiological evaluation of temocillin for bloodstream infections with Enterobacterales: a Belgian single-centre retrospective study

Clinical and microbiological evaluation of temocillin for bloodstream infections with Enterobacterales: a Belgian single-centre retrospective study

Interpretive criteria for temocillin disk diffusion susceptibility testing

Desacetylcefotaxime

Contact Info

Product

Resources

About